Tech Company Financing Transactions
Nura Bio Funding Round
The Column Group, Euclidean Capital and Samsara BioCapital participated in a $73.8 million Series B funding round for Nura Bio. The round was announced on 6/22/2026.
Transaction Overview
Company Name
Announced On
6/22/2026
Transaction Type
Venture Equity
Amount
$73,800,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of the clinical pipeline, including the Phase 1b/2a study of NB-4746, its oral, brain-penetrant SARM1 inhibitor, which recently commenced dosing in ALS patients.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
171 Oyster Point Blvd 401
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Nura Bio was conceived in 2018 by The Column Group and its scientific founders to revolutionize the treatment of neurological diseases with novel, life-changing neuroprotective medicines. By transforming recent scientific breakthroughs in axonal degeneration and neuroimmune regulation into neuroprotective medicines, we aim to offer renewed hope for those affected by serious neurological diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shilpa Sambashivan
VP - Bus. Development
David Lau
Browse more venture capital transactions:
Prev: 6/22/2026: WaiV Robotics venture capital transaction
Next: 6/22/2026: American Perpetuals Exchange venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record tech company VC transactions. VC transactions on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs